Glioblastoma Multiforme Treatment Market Expected to Reach US ~$4.82 billion and CAGR 8.9% by 2030 – Polaris Market Research
The global Glioblastoma Multiforme (GBM) Treatment Market size is expected to reach USD 4.82 billion by 2030 according to a new study by Polaris Market Research.
The growing cases of brain tumors globally, along with glioblastoma multiforme, are the chief impelling factor that caters to the market growth. Besides, the rising number of R&D activities for the effective surgery alternative, the growing geriatric population, the introduction of updated techniques for diagnosis, and rapid advancements in drug delivery technologies may further act as a catalyzing factor for the global industry demand in the foreseen period.
Request Sample Copy of Research Report @ https://www.polarismarketresearch.com/industry-analysis/glioblastoma-multiforme-gbm-treatment-market/request-for-sample
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
Based on the drug class, the other segment is the dominating segment and is projected to lead the industry in the forthcoming years. It includes drugs such as corticosteroids, everolimus, and 5-aminolevulinic acid (5-ALA). These drugs are mainly prescribed to decrease the peritumoral vasogenic edema for symptomatic benefits, and for lack of mineralocorticoid activity. Whereas the bevacizumab segment is expected to rise at the highest CAGR in the foreseen years. It is a targeted approved therapy for curing frequent and recent diagnosed GBM. Thereby, the continuation of a medical study for using bevacizumab with other therapies is likely to augment the adoption of the drug for the management of GBM.
The demand for novel and competent drugs is increasing because they are more likely to present effective surgery. For instance, as per the study by National Centre for Biotechnology Information (NCBI), in 2019, the patient pool of glioblastoma increased to 3.19 per 100,000, in 2017. Accordingly, this is an alarming growth rate because the fatality of the patients is exponentially grown owing to the unavailability of the appropriate surgery. This growth requires effective therapies and drugs that help in decreasing the number of fatalities and may increase the life expectancy rate of the patients. Therefore, these are the certain factors that may create a lucrative opportunity for market growth around the world.
There are various industry vendors introducing their innovations across the global industry to reinforce their geographical footprints. For instance, in April 2021, Humanigen Inc.- a clinical-stage biopharmaceutical company, declared the positive results from its Phase 1 clinical trial of “Ifabotuzumab” in the surgery of glioblastoma multiforme. The company announces the positive results of its Humaneered antibody, Ifabotuzumab. The drug was confirmed to be very responsive, precise, and reproducible in targeting the tumor and tumor microenvironment in all patients.
Buy a Premium Report – https://www.polarismarketresearch.com/checkouts/11521
Market participants such as Merck & Co., Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Amgen, Inc., Arbor Pharmaceuticals, LLC, Amgen, Inc., Teva Pharmaceutical Industries Ltd., Karyopharm Therapeutics, Inc., and Pfizer Inc. are some of the key players operating in the global industry.
Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/glioblastoma-multiforme-gbm-treatment-market/inquire-before-buying
(You may enquire about a reported quote OR available discount offers to our sales team before purchase.)
Polaris Market research has segmented the glioblastoma multiforme (GBM) treatment market report on the basis of treatment, drug class, end-use, and region:
Glioblastoma Multiforme (GBM) Treatment, Treatment Outlook (Revenue – USD Billion, 2018 – 2030)
- Surgery
- Radiation therapy
- Chemotherapy
- Targeted Therapy
- Tumor Treating Field (TTF) Therapy
- Immunotherapy
Glioblastoma Multiforme (GBM) Treatment, Drug Class Outlook (Revenue – USD Billion, 2018 – 2030)
- Temozolomide
- Bevacizumab
- Lomustine
- Carmustine Wafers
- Others
Glioblastoma Multiforme (GBM) Treatment, End-use Outlook (Revenue – USD Billion, 2018 – 2030)
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Browse detailed report with in-depth TOC – Glioblastoma Multiforme (GBM) Treatment Market
About Us:
Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semiconductors, chemicals, automotive, and aerospace & defense, among different ventures, present globally.
Contact Us:
Polaris Market Research
Phone: +1-929-297-9727